Bearish
Harbour BioMed Wins $20 Million Patent Verdict Against Amgen
A U.S. jury has found Amgen Inc. liable for patent infringement against Harbour BioMed, awarding the drug developer $20.2 million in damages. The verd...
AMGN
--
--
--
--
Price Chart (30 Days)
Ad Space
Analyst Sentiment
Bullish (34)
Neutral (37)
Bearish (3)
Latest AMGN News
Bearish
Neutral
Van ECK Associates Corp Lowers Position in Amgen Inc. $AMGN
Van ECK Associates Corp significantly reduced its stake in Amgen Inc. by 39.8% in Q4, selling over 540,000 shares. Despite this, other institutional i...
Neutral
Here’s Why Amgen (AMGN) is Among the 7 Best Longevity Stocks to Buy Now
Amgen Inc. (NASDAQ:AMGN) is highlighted as one of the top 7 longevity stocks to consider. The company recently announced positive Phase 3 data for its...
Neutral
Amgen Seeks FDA Hearing To Challenge Proposed Tavneos Withdrawal
Amgen has formally requested an FDA hearing to challenge the proposed withdrawal of its drug Tavneos, arguing that the benefits for patients with ANCA...
Neutral
Price to earnings ratio of Amgen Inc. Shs Cert Deposito Arg Repr 0.033333 Shs – BCBA:AMGN.CI
This article provides the price to earnings ratio for Amgen Inc. Shs Cert Deposito Arg Repr 0.033333 Shs (BCBA:AMGN.CI). It notes that the market is c...
Neutral
Xponance LLC Raises Position in Amgen Inc. $AMGN
Xponance LLC increased its stake in Amgen Inc. by 5.3% in the fourth quarter, bringing its total holdings to 125,333 shares valued at approximately $4...
Neutral
Dow's 750-Point Rally Led By Gains In Shares Of Amgen, Boeing
The Dow Jones Industrial Average experienced a significant 750-point rally, driven primarily by strong performances from Amgen and Boeing shares. This...
Neutral
Franklin Resources Inc. Has $712.09 Million Stake in Amgen Inc. $AMGN
Franklin Resources Inc. significantly reduced its stake in Amgen Inc. by 17.7% in the fourth quarter, yet still holds 2.18 million shares valued at ab...
Neutral
Can MariTide Save Amgen Stock From Its Fading Blockbusters?
Amgen's stock has outperformed the S&P 500 recently, driven by investor focus on its obesity drug, MariTide, as key blockbusters like Prolia and XGEVA...
Bullish
O Shaughnessy Asset Management LLC Buys 27,035 Shares of Amgen Inc. $AMGN
O Shaughnessy Asset Management LLC increased its stake in Amgen Inc. (NASDAQ:AMGN) by 25.7% in the fourth quarter, acquiring an additional 27,035 shar...
Bullish
Hilton Head Capital Partners LLC Purchases Shares of 3,798 Amgen Inc. $AMGN
Hilton Head Capital Partners LLC initiated a new position in Amgen Inc. during the fourth quarter, acquiring 3,798 shares valued at approximately $1.2...
Bullish
What to know about MariTide, Amgen’s experimental GLP-1 drug
Amgen is developing MariTide, an experimental monthly GLP-1 injection, which aims to improve convenience and patient adherence compared to weekly dose...
Bullish
What to know about MariTide, Amgen’s experimental GLP-1 drug
Amgen is developing MariTide, an experimental GLP-1 drug, which aims to improve convenience and adherence with monthly injections instead of weekly on...
Neutral
Amgen Inc. $AMGN Shares Sold by Capital International Ltd. CA
Capital International Ltd. CA reduced its holdings in Amgen Inc. (NASDAQ:AMGN – Free Report) by 51.2% during the 4th quarter, according to the company...
Bullish
Should Amgen’s (AMGN) IMDYLLTRA Win and Rare-Disease Data Shift Its High-Need Portfolio Strategy?
Amgen recently received European marketing authorization for IMDYLLTRA (tarlatamab) for extensive-stage small cell lung cancer and presented positive ...
Bullish
Vestcor Inc Sells 10,133 Shares of Amgen Inc. $AMGN
Vestcor Inc. significantly reduced its stake in Amgen Inc. by selling 10,133 shares, leaving them with 19,353 shares valued at approximately $6.33 mil...
Neutral
Amgen Inc. $AMGN Position Boosted by Vise Technologies Inc.
Vise Technologies Inc. significantly increased its stake in Amgen Inc. (NASDAQ:AMGN) by 66.4% in the fourth quarter, bringing its total holdings to 19...
Neutral
J.W. Cole Advisors Inc. Sells 6,407 Shares of Amgen Inc. $AMGN
J.W. Cole Advisors Inc. reduced its stake in Amgen Inc. by 27.6% in the Q4, selling 6,407 shares and now owning 16,789 shares valued at $5.495 million...
Neutral
Goldman Sachs Maintains Amgen(AMGN.US) With Buy Rating, Cuts Target Price to $389
Goldman Sachs has reaffirmed its Buy rating for Amgen (AMGN.US) but has adjusted its target price downwards to $389. This indicates a continued positi...
Neutral
Is There Still Opportunity In Amgen (AMGN) After Its 24% One-Year Share Price Gain
Amgen's stock has seen a 24% gain over the past year, prompting an assessment of its current valuation. Simply Wall St's model indicates that Amgen (A...
Research AMGN on:
Ad Space